Effect of omega-3 and D-chiro inositol compared to D-chiro inositol alone on hormonal parameters in women with insulin resistant polycystic ovary syndrome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20251971Keywords:
Omega-3, D-chiro inositol, Hormonal parameters, Insulin resistant polycystic ovary syndromeAbstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder marked by high androgen levels, irregular ovulation, and ovarian cysts. Recommended treatments include lifestyle and nutrition changes alongside medication. Omega-3 fatty acids support immune function, insulin sensitivity, cell health, and ovulation. D-chiro Inositol helps lower blood pressure, triglycerides, and glucose, enhances ovarian function, and reduces harmful oxidative stress in the ovaries. This study was designed to evaluate and compare the effect of omega-3 and D-chiro inositol and effect of D-chiro inositol alone on hormonal parameters in women with insulin resistant PCOS.
Methods: This randomized controlled trail study was conducted in the departments of reproductive endocrinology and infertility, Bangbandhu Sheikh Mujib medical university, Dhaka from January 2023 to June 2024. Total 60 individuals with PCOS were observed in this study.
Results: The mean age was 24.88 (±4.81) years and mean BMI was 28.83 (±2.72) kg/m2. In group A, omega-3 plus D-chiro-inositol therapy is found more effective than D-chiro-inositol alone in reducing serum luteinizing hormone (LH), (follicle stimulating hormone) FSH, free testosterone and fasting glucose, fasting insulin and homeostasis model assessment for insulin resistance (HOMA-IR) after 12 weeks of treatment. But there was no statistically significant difference in post treatment LH, FSH, free testosterone, fasting glucose, fasting insulin and HOMA-IR between 2 groups.
Conclusions: Combining D-chiro inositol and omega-3 fatty acids can significantly improve insulin sensitivity and reduce the levels of LH, FSH and free testosterone in women with PCOS. But there is no significant difference in this post treatment hormonal and biochemical parameters between the two groups.
Metrics
References
Banaszewska B, Pawelczyk L, Spaczynski R. Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome. Reprod Biol. 2019;19(4):309-15. DOI: https://doi.org/10.1016/j.repbio.2019.09.006
Farrell K, Antoni MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril. 2010;94(5):1565-74. DOI: https://doi.org/10.1016/j.fertnstert.2010.03.081
Regidor PA, Mueller A, Sailer M, Gonzalez Santos F, Rizo JM, Moreno Egea F. Chronic inflammation in PCOS: the potential benefits of specialized pro-resolving lipid mediators (SPMs) in the improvement of the resolutive response. Int J Mol Sci. 2020;22(1):384. DOI: https://doi.org/10.3390/ijms22010384
Lee H, Oh JY, Sung YA, Chung H. Is insulin resistance an intrinsic defect in Asian polycystic ovary syndrome? Yonsei Med J. 2013;54(3):609-14. DOI: https://doi.org/10.3349/ymj.2013.54.3.609
Nardo LG, Patchava S, Laing I. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. Panminerva Med. 2008;50(4):267-78.
Faghfoori Z, Fazelian S, Shadnoush M, Goodarzi R. Nutritional management in women with polycystic ovary syndrome: A review study. Diabetes Metab Syndr. 2017;11(2):S429-32. DOI: https://doi.org/10.1016/j.dsx.2017.03.030
Albracht-Schulte K, Kalupahana NS, Ramalingam L, Wang S, Rahman SM, Robert-McComb J, et al. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J Nutr Biochem. 2018;58:1-16. DOI: https://doi.org/10.1016/j.jnutbio.2018.02.012
Khani B, Mardanian F, Fesharaki SJ. Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome. J Res Med Sci. 2017;22(1):64. DOI: https://doi.org/10.4103/jrms.JRMS_644_16
Mohammadi E, Rafraf M. Benefits of omega-3 fatty acids supplementation on serum paraoxonase 1 activity and lipids ratios in polycystic ovary syndrome. Health Promot Perspect. 2012;2(2):197.
Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122(1-3):42-52. DOI: https://doi.org/10.1016/j.jsbmb.2009.12.010
Karakas SE, Perroud B, Kind T, Palazoglu M, Fiehn O. Changes in plasma metabolites and glucose homeostasis during omega-3 polyunsaturated fatty acid supplementation in women with polycystic ovary syndrome. BBA Clin. 2016;5:179-85. DOI: https://doi.org/10.1016/j.bbacli.2016.04.003
Nadjarzadeh A, Dehghani-Firouzabadi R, Daneshbodi H, Lotfi MH, Vaziri N, Mozaffari-Khosravi H. Effect of omega-3 supplementation on visfatin, adiponectin, and anthropometric indices in women with polycystic ovarian syndrome. J Reprod Infertil. 2015;16(4):212.
Ebrahimi FA, Samimi M, Foroozanfard F, Jamilian M, Akbari H, Rahmani E, et al. The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Exp Clin Endocrinol Diabetes. 2017;125(6):353-9. DOI: https://doi.org/10.1055/s-0042-117773
Akhter D, Banu J, Yasmin M, Sultana N, Munmun SA. Effect of D-chiro-inositol on hormonal parameters and insulin resistance in women with polycystic ovary syndrome. Int J Reprod Contracept Obstet Gynecol. 2023;12:1992-7. DOI: https://doi.org/10.18203/2320-1770.ijrcog20231909
Lu L, Li X, Lv L, Xu Y, Wu B, Huang C. Associations between omega-3 fatty acids and insulin resistance and body composition in women with polycystic ovary syndrome. Front Nutr. 2022;9:1016943. DOI: https://doi.org/10.3389/fnut.2022.1016943
Troisi J, Cinque C, Giugliano L, Symes S, Richards S, Adair D, et al. Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study. J Ovarian Res. 2019;12(1):25. DOI: https://doi.org/10.1186/s13048-019-0500-x
Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int J Endocrinol. 2016;2016:320-24. DOI: https://doi.org/10.1155/2016/3204083
Onyegbule OA, Meludu SC, Dioka CE, Okwara JE, Obi-Ezeani CN, Njoku CM. Effect of omega‑3 supplementation on serum adiponectin and fertility hormones in women with polycystic ovarian syndrome. J Appl Sci Clin Pract. 2022;3:43-8. DOI: https://doi.org/10.4103/jascp.jascp_8_22
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565-92. DOI: https://doi.org/10.1210/jc.2013-2350
Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G. Metabolism and ovarian function in PCOS women: a therapeutic approach with Inositols. Int J Endocrinol. 2016;2016:6306410. DOI: https://doi.org/10.1155/2016/6306410
Yang K, Zeng L, Bao T. Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2018;16:27. DOI: https://doi.org/10.1186/s12958-018-0346-x
Yuan J, Wen X, Jia M. Efficacy of omega-3 polyunsaturated fatty acids on hormones, oxidative stress, and inflammatory parameters among polycystic ovary syndrome: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(8):8991-9001. DOI: https://doi.org/10.21037/apm-21-2018
Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347-63. DOI: https://doi.org/10.1093/humupd/dmq001
Salek M, Clark CCT, Taghizadeh M, Jafarnejad S. N-3 fatty acids as preventive and therapeutic agents in attenuating PCOS complications. EXCLI J. 2019;18:558-75.
Downloads
Published
How to Cite
Issue
Section
